TY - JOUR
T1 - A clinical calculator for predicting intraoperative blood loss and transfusion risk in spine tumor patients
AU - Pennington, Zach
AU - Ehresman, Jeff
AU - Feghali, James
AU - Schilling, Andrew
AU - Hersh, Andrew
AU - Hung, Bethany
AU - Lubelski, Daniel
AU - Sciubba, Daniel M.
N1 - Funding Information:
This study was not supported by any kind of funding. Author Disclosures: ZP: Nothing to disclose. JE: Nothing to disclose. JF: Nothing to disclose. AS: Nothing to disclose. AH: Nothing to disclose. BH: Nothing to disclose. DL: Nothing to disclose. DMS: Consulting: Baxter (C), DePuy-Synthes (D), Ethicon (B), Globus Medical (B), K2M (C), Medical devices (E), Medtronic (C), NuVasive (B), Stryker (F); Trips/Travel: Baxter (A), DePuy-Synthes (B), Globus Medical (B), K2M (B), Medical devices (C), Medicrea (B) Medtronic (C), NuVasive (B), Stryker (C), Synthes (C); Grants: Baxter Medical (D), North American Spine Society (C), Stryker (E).
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/2
Y1 - 2021/2
N2 - BACKGROUND CONTEXT: Surgery for vertebral column tumors is commonly associated with intraoperative blood loss (IOBL) exceeding 2 liters and the need for transfusion of allogeneic blood products. Transfusion of allogeneic blood, while necessary, is not benign, and has been associated with increased rates of wound complication, venous thromboembolism, delirium, and death. PURPOSE: To develop a prediction tool capable of predicting IOBL and risk of requiring allogeneic transfusion in patients undergoing surgery for vertebral column tumors. STUDY DESIGN/SETTING: Retrospective, single-center study. PATIENT SAMPLE: Consecutive series of 274 patients undergoing 350 unique operations for primary or metastatic spinal column tumors over a 46-month period at a comprehensive cancer center OUTCOME MEASURES: IOBL (in mL), use of intraoperative blood products, and intraoperative blood products transfused. METHODS: We identified IOBL and transfusions, along with demographic data, preoperative laboratory data, and surgical procedures performed. Independent predictors of IOBL and transfusion risk were identified using multivariable regression. RESULTS: Mean age at surgery was 57.0±13.6 years, 53.1% were male, and 67.1% were treated for metastatic lesions. Independent predictors of IOBL included en bloc resection (p<.001), surgical invasiveness (β=25.43 per point; p<0.001), and preoperative albumin (β=−244.86 per g/dL; p=0.011). Predictors of transfusion risk included preoperative hematocrit (odds ratio [OR]=0.88 per %; 95% confidence interval [CI, 0.84, 0.93]; p<0.001), preoperative MCHgb (OR=0.88 per pg; 95% CI [0.78, 1.00]; p=0.048), preoperative red cell distribution width (OR=1.32 per %; 95% CI [1.13, 1.55]; p<0.001), en bloc resection (OR=3.17; 95%CI [1.33, 7.54]; p=0.009), and surgical invasiveness (OR=1.08 per point; [1.06; 1.11]; p<0.001). The transfusion model showed a good fit of the data with an optimism-corrected area under the curve of 0.819. A freely available, web-based calculator was developed for the transfusion risk model (https://jhuspine3.shinyapps.io/TRUST/). CONCLUSIONS: Here we present the first clinical calculator for intraoperative blood loss and transfusion risk in patients being treated for primary or metastatic vertebral column tumors. Surgical invasiveness and preoperative microcytic anemia most strongly predict transfusion risk. The resultant calculators may prove clinically useful for surgeons counseling patients about their individual risk of requiring allogeneic transfusion.
AB - BACKGROUND CONTEXT: Surgery for vertebral column tumors is commonly associated with intraoperative blood loss (IOBL) exceeding 2 liters and the need for transfusion of allogeneic blood products. Transfusion of allogeneic blood, while necessary, is not benign, and has been associated with increased rates of wound complication, venous thromboembolism, delirium, and death. PURPOSE: To develop a prediction tool capable of predicting IOBL and risk of requiring allogeneic transfusion in patients undergoing surgery for vertebral column tumors. STUDY DESIGN/SETTING: Retrospective, single-center study. PATIENT SAMPLE: Consecutive series of 274 patients undergoing 350 unique operations for primary or metastatic spinal column tumors over a 46-month period at a comprehensive cancer center OUTCOME MEASURES: IOBL (in mL), use of intraoperative blood products, and intraoperative blood products transfused. METHODS: We identified IOBL and transfusions, along with demographic data, preoperative laboratory data, and surgical procedures performed. Independent predictors of IOBL and transfusion risk were identified using multivariable regression. RESULTS: Mean age at surgery was 57.0±13.6 years, 53.1% were male, and 67.1% were treated for metastatic lesions. Independent predictors of IOBL included en bloc resection (p<.001), surgical invasiveness (β=25.43 per point; p<0.001), and preoperative albumin (β=−244.86 per g/dL; p=0.011). Predictors of transfusion risk included preoperative hematocrit (odds ratio [OR]=0.88 per %; 95% confidence interval [CI, 0.84, 0.93]; p<0.001), preoperative MCHgb (OR=0.88 per pg; 95% CI [0.78, 1.00]; p=0.048), preoperative red cell distribution width (OR=1.32 per %; 95% CI [1.13, 1.55]; p<0.001), en bloc resection (OR=3.17; 95%CI [1.33, 7.54]; p=0.009), and surgical invasiveness (OR=1.08 per point; [1.06; 1.11]; p<0.001). The transfusion model showed a good fit of the data with an optimism-corrected area under the curve of 0.819. A freely available, web-based calculator was developed for the transfusion risk model (https://jhuspine3.shinyapps.io/TRUST/). CONCLUSIONS: Here we present the first clinical calculator for intraoperative blood loss and transfusion risk in patients being treated for primary or metastatic vertebral column tumors. Surgical invasiveness and preoperative microcytic anemia most strongly predict transfusion risk. The resultant calculators may prove clinically useful for surgeons counseling patients about their individual risk of requiring allogeneic transfusion.
KW - Clinical calculator
KW - Intraoperative blood loss
KW - Primary spine tumor
KW - Spine metastasis
KW - Spine tumors
KW - Surgical invasiveness
KW - Transfusion
UR - http://www.scopus.com/inward/record.url?scp=85092365892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092365892&partnerID=8YFLogxK
U2 - 10.1016/j.spinee.2020.09.011
DO - 10.1016/j.spinee.2020.09.011
M3 - Article
C2 - 33007469
AN - SCOPUS:85092365892
SN - 1529-9430
VL - 21
SP - 302
EP - 311
JO - Spine Journal
JF - Spine Journal
IS - 2
ER -